A randomized prospective study using secretin-enhanced pancreatic juice cytology in the diagnosis of pancreatic cancer.

A randomized prospective study using secretin-enhanced pancreatic juice cytology in the diagnosis of pancreatic cancer. - The effect of secretin-enhanced pancreatic juice cytology

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013762

Enrollment

240

Registered

2014-04-21

Start date

2014-04-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic disease

Interventions

Administration of Secretin Non-administration of Secretin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients suspected of pancreatic cancer reffered for ERCP

Exclusion criteria

Exclusion criteria: 1. Patients with acute pancreatitis 2. Patients with allergy for secretin 3. Patients unable to understand and sign informed consent

Design outcomes

Primary

Measure	Time frame
Primary outcome measurement is accuracy of cytology of pancreatic juice	—

Countries

Japan

Contacts

Public ContactNobuyasu Fukutake

Osaka Medical Center for Cancer and Cardiovascular Disease Department of Hepatobiliary Pancreatic Oncology

fukutake-no@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026